DK1150991T3 - Præparater til behandling af inflammatoriske reaktioner - Google Patents

Præparater til behandling af inflammatoriske reaktioner

Info

Publication number
DK1150991T3
DK1150991T3 DK00905833T DK00905833T DK1150991T3 DK 1150991 T3 DK1150991 T3 DK 1150991T3 DK 00905833 T DK00905833 T DK 00905833T DK 00905833 T DK00905833 T DK 00905833T DK 1150991 T3 DK1150991 T3 DK 1150991T3
Authority
DK
Denmark
Prior art keywords
preparations
treatment
inflammatory reactions
inflammatory
reactions
Prior art date
Application number
DK00905833T
Other languages
Danish (da)
English (en)
Inventor
Joel M Linden
Gail W Sullivan
Ian J Sarembock
Timothy Macdonald
Mark Okusa
Irving L Kron
W Michael Scheld
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/333,387 external-priority patent/US6232297B1/en
Application filed by Univ Virginia filed Critical Univ Virginia
Application granted granted Critical
Publication of DK1150991T3 publication Critical patent/DK1150991T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00905833T 1999-02-01 2000-01-31 Præparater til behandling af inflammatoriske reaktioner DK1150991T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11802999P 1999-02-01 1999-02-01
US12431699P 1999-03-12 1999-03-12
US13337499P 1999-05-10 1999-05-10
US13557399P 1999-05-24 1999-05-24
US09/333,387 US6232297B1 (en) 1999-02-01 1999-06-15 Methods and compositions for treating inflammatory response
US15141299P 1999-08-30 1999-08-30

Publications (1)

Publication Number Publication Date
DK1150991T3 true DK1150991T3 (da) 2004-06-07

Family

ID=27557920

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00905833T DK1150991T3 (da) 1999-02-01 2000-01-31 Præparater til behandling af inflammatoriske reaktioner

Country Status (25)

Country Link
EP (1) EP1150991B1 (https=)
JP (1) JP4837831B2 (https=)
KR (1) KR100668006B1 (https=)
CN (1) CN1191266C (https=)
AR (1) AR029332A1 (https=)
AT (1) ATE263777T1 (https=)
AU (2) AU778870B2 (https=)
BR (1) BR0007864A (https=)
CA (1) CA2361614C (https=)
CZ (1) CZ296404B6 (https=)
DE (1) DE60009665T2 (https=)
DK (1) DK1150991T3 (https=)
EE (1) EE05185B1 (https=)
ES (1) ES2215609T3 (https=)
HU (1) HU228937B1 (https=)
IL (2) IL144188A0 (https=)
MX (1) MXPA01007850A (https=)
MY (1) MY129445A (https=)
NO (1) NO321216B1 (https=)
NZ (1) NZ513096A (https=)
PL (1) PL199953B1 (https=)
PT (1) PT1150991E (https=)
SK (1) SK284877B6 (https=)
UA (1) UA72912C2 (https=)
WO (1) WO2000044763A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
NZ556354A (en) 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
US20050033044A1 (en) 2003-05-19 2005-02-10 Bristol-Myers Squibb Pharma Company Methods for preparing 2-alkynyladenosine derivatives
AU2005231440B9 (en) * 2004-04-02 2012-02-23 Dogwood Pharmaceuticals, Inc. Selective antagonists of A2A adenosine receptors
US7396825B2 (en) * 2004-05-03 2008-07-08 University Of Virginia Patent Foundation Agonists of A2A adenosine receptors for treatment of diabetic nephropathy
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
US8178509B2 (en) 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
EP2021350B1 (en) 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Phosphorylated a2a receptor agonists
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
AU2007263728A1 (en) * 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Adenosine derivatives for the treatment of pain
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
KR20110028531A (ko) * 2008-07-03 2011-03-18 유니버시티 오브 버지니아 페이턴트 파운데이션 아파데노손의 단위 용량
BRPI1014224A2 (pt) 2009-06-30 2019-09-24 Forest Laboratories Holdings Ltd composto, composição farmacêutica,e, método para tratar um estado.
FR2960876B1 (fr) 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
CN114096552B (zh) * 2019-06-21 2024-09-27 中国人民解放军军事科学院军事医学研究院 具有a2a腺苷受体拮抗作用的小分子化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3537228A1 (de) * 1985-10-19 1987-04-23 Huels Chemische Werke Ag Verfahren zur herstellung von cyclohexylverbindungen
JPS6299330A (ja) * 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd 抗高血圧剤
EP0444196B1 (en) * 1988-11-15 1994-06-08 Yamasa Shoyu Kabushiki Kaisha Agent for treatment and prophylaxis of ischemic disease of heart or brain
ES2077070T3 (es) * 1989-06-20 1995-11-16 Yamasa Shoyu Kk Intermedio de sintesis de 2-alquiniladenosina, produccion de dicho intermedio, produccion de 2-alquiniladenosina a partir de dicho intermedio, y derivado de 2-alquiniladenosina estable.
WO1991009864A1 (fr) * 1990-01-04 1991-07-11 Yamasa Shoyu Kabushiki Kaisha Medicament pour le traitement d'affections ischemiques du c×ur ou du cerveau
JPH03287537A (ja) * 1990-03-31 1991-12-18 Yamasa Shoyu Co Ltd 抗動脈硬化症剤
JP3025559B2 (ja) * 1990-07-19 2000-03-27 ヤマサ醤油株式会社 アデノシン誘導体
JP3025557B2 (ja) * 1991-06-28 2000-03-27 ヤマサ醤油株式会社 ２‐アルキニルアデノシン誘導体
JP3053908B2 (ja) * 1991-06-28 2000-06-19 ヤマサ醤油株式会社 ２‐アルキニルアデノシン誘導体
IT1254915B (it) * 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
AU7449598A (en) * 1997-05-23 1998-12-11 Nippon Shinyaku Co. Ltd. Medicinal composition for prevention or treatment of hepatopathy
AU740770B2 (en) * 1997-06-18 2001-11-15 Aderis Pharmaceuticals, Inc. Compositions and methods for preventing restenosis following revascularization procedures
JPH11335302A (ja) * 1998-05-26 1999-12-07 Toa Eiyo Ltd 安定な医薬組成物
JP3619017B2 (ja) * 1998-06-24 2005-02-09 日本臓器製薬株式会社 新規アラビノシルアデニン誘導体
JP2002173427A (ja) * 1998-09-01 2002-06-21 Yamasa Shoyu Co Ltd 眼疾患治療用医薬組成物

Also Published As

Publication number Publication date
CZ296404B6 (cs) 2006-03-15
EE05185B1 (et) 2009-06-15
WO2000044763A3 (en) 2000-12-14
CN1357002A (zh) 2002-07-03
AU778870B2 (en) 2004-12-23
NO20013507L (no) 2001-09-18
CN1191266C (zh) 2005-03-02
JP2002536300A (ja) 2002-10-29
AU2745400A (en) 2000-08-18
MXPA01007850A (es) 2002-08-20
HUP0200224A3 (en) 2005-02-28
IL144188A (en) 2008-12-29
EP1150991A2 (en) 2001-11-07
KR100668006B1 (ko) 2007-01-15
JP4837831B2 (ja) 2011-12-14
AR029332A1 (es) 2003-06-25
ATE263777T1 (de) 2004-04-15
DE60009665T2 (de) 2004-08-19
AU2005201255B2 (en) 2008-02-28
CA2361614C (en) 2008-08-26
UA72912C2 (uk) 2005-05-16
DE60009665D1 (de) 2004-05-13
NZ513096A (en) 2003-01-31
BR0007864A (pt) 2001-11-06
PL199953B1 (pl) 2008-11-28
SK10972001A3 (sk) 2002-01-07
HUP0200224A2 (en) 2002-06-29
KR20020013494A (ko) 2002-02-20
NO20013507D0 (no) 2001-07-13
PT1150991E (pt) 2004-08-31
CZ20012781A3 (cs) 2002-01-16
HU228937B1 (en) 2013-06-28
NO321216B1 (no) 2006-04-03
HK1047288A1 (en) 2003-02-14
WO2000044763A2 (en) 2000-08-03
CA2361614E (en) 2000-08-03
MY129445A (en) 2007-04-30
SK284877B6 (sk) 2006-01-05
EP1150991B1 (en) 2004-04-07
EE200100397A (et) 2002-08-15
AU2005201255A1 (en) 2005-04-21
IL144188A0 (en) 2002-05-23
CA2361614A1 (en) 2000-08-03
ES2215609T3 (es) 2004-10-16

Similar Documents

Publication Publication Date Title
DK1150991T3 (da) Præparater til behandling af inflammatoriske reaktioner
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK0966447T3 (da) Anvendelige små molekyler til behandling af betændelsessygdomme
DK1028954T3 (da) Substituerede imidazoler egnede til behandling af inflammatoriske sygdomme
DK1165576T3 (da) Fremgangsmåde til fremstilling af amin-platin-komplekser
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
EE200200172A (et) Ühendid isheemia ravimiseks
DK1093370T3 (da) Farmaceutisk præparat til behandling af diabetes
DK1176195T3 (da) Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
DK2412368T3 (da) Sammensætning til behandling af ar
EE200100483A (et) Põletikuvastaste vahenditena kasutatavad ühendid
IS6040A (is) Valdekoxib efnablöndur
DK1223927T3 (da) Anvendelse af retigabin til behandling af neuropatiske smerter
IS2223B (is) Aðferð til framleiðslu á 5-sýanóþalíði
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
DK1176964T3 (da) Brug af ET743 til behandling af cancer
DK199800837A (da) Anlæg til behandling af emner
DK1206436T3 (da) Retinoider til behandling af emfysem
NO20035540D0 (no) Eksoterme preparater til behandling av ektoparasitter
DK1028960T3 (da) Fremgangsmåde til fremstilling af thiazolidinedion
DK1187833T3 (da) Fremgangsmåde til fremstilling af thiamethoxam
DE60028852D1 (de) Fixiervorrichtung
DK1200447T3 (da) Oxazinocarbazoler til behandling af CNS-sygdomme
DK1203000T3 (da) Fremgangsmåde til fremstilling af phosphonomethylglycin